ArticleInflammatory bowel diseases2024
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.
Article in Inflammatory bowel diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 8 citations in OpenAlex.
- Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making.Digestive diseases and sciences · 2026Article
- IBD Nurse-Led Clinical Pathways to Optimize Patient Safety in Advanced Therapies: A Narrative Review.Digestive diseases and sciences · 2026Review
- Severity or Incidence: Labeling Side-Effect Attributes in Discrete Choice Experiments.The patient · 2026Article
- Article
- Advanced therapy options, choice, access, and treatment empowerment for inflammatory bowel disease (ADVOCATE-IBD): a UK-wide semi-structured interview study exploring patient preferences around advanced therapy decisions in inflammatory bowel disease.Crohn's & colitis 360 · 2026Article
- Knowledge Gaps, Treatment Preferences, and Unmet Clinical Needs Among Patients With Inflammatory Bowel Disease: A Cross-Sectional Study.The Kaohsiung journal of medical sciences · 2026Article
- Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First-Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries.United European gastroenterology journal · 2026Article
- Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review.Advances in therapy · 2026Review
- Preferences, Expectations and Management Satisfaction in IBD Patients: A Cross-Sectional Questionnaire-Based Study.Journal of clinical medicine · 2026Article
- Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision Making.Research square · 2026Article
- A snapshot of subcutaneous infliximab uses in inflammatory rheumatic diseases: a multicentric Italian study.Therapeutic advances in musculoskeletal disease · 2026Article
- Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study.Therapeutic advances in gastroenterology · 2026Article
- Quantifying patient preferences for inpatient pharmacist consultation: a multi-center discrete choice experiment in Sichuan, China.Frontiers in public health · 2026Article
- Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries.Advances in therapy · 2025Article
- Discrete choice experiment on the preferences for continuing medical education training programs among primary health care physicians in China.BMC medical education · 2025Article
- Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.Crohn's & colitis 360 · 2024Article
- Patients' and gastroenterologists' preferences regarding outcomes and medication attributes in ulcerative colitis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundInflammatory bowel disease requires long-term treatment; therefore, understanding patient preferences is important in aiding informed treatment decision making. This study explored patients' preferences for treatment attributes of available inflammatory bowel disease therapies.
methodsAdult patients from 7 European countries who self-reported previous/current treatment for Crohn's disease (CD) or ulcerative colitis (UC) participated in an online survey via the Carenity platform. In a discrete choice experiment, the relative importance of treatment attributes for CD and UC was estimated using conditional logit models. Latent class analysis was conducted to estimate heterogeneous treatment preferences based on patient profiles. Patients' perspectives and preferences regarding their quality of life were assessed.
resultsAcross 686 completed survey responses (CD, n = 360; UC, n = 326), the mean patient age was 48 and 50 years, respectively. Patients with CD ranked route of administration as the most important attribute (attribute importance: 32%), preferring subcutaneous over intravenous treatment (P < .001). Patients with UC ranked route of administration and frequency of serious adverse events as the most important attributes (attribute importance: 31% and 23%, respectively), preferring oral (P < .001) and subcutaneous (P < .001) over intravenous treatment and treatment that minimized the risk of serious adverse events (P < .001) or mild adverse events (P < .01). Latent class analyses confirmed the impact of patients' sociodemographic profile on their preferences. All patients prioritized general well-being, energy level, and daily activities as the most important aspects for improvement through treatment.
conclusionsPatient preferences for treatment attributes varied among patients with CD or UC, highlighting the importance of personalized care and shared decision making to maximize treatment benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.